title: Human recombinant interleukin-4 (HurIL-4) improves SCID mouse reconstitution with human peripheral blood lymphocytes.
abstract: The application of human-scid mouse chimera (hu-scid) technology has some limitations, because of the variable amounts and functional heterogeneity of human cells recovered from engrafted mice. Attempts to optimize the construction of hu-scid chimeras with human peripheral blood mononuclear cells (Hu-PBMC) by using in vivo anti-asialo GM1 antibody treatment in mice in order to eliminate natural killer cells have been published by other authors with interesting results. In this study, Hu-PBMC were incubated in vitro with human recombinant interleukin-4 (HurIL-4) or human recombinant interleukin-2 (HurIL-2) for two hours and were intraperitoneally transferred into scid mice. Total human IgM and IgG levels in hu-scid sera, human cell markers in the thymus and in the spleen of grafted mice were considered as parameters of successful engraftment. HurIL-4 significantly enhanced human immunoglobulin production while HurIL-2 did not show any obvious effect. Human cell markers (CD2 and CD19) were significantly higher in the group of HurIL-4 treated Hu-PBMC than in the other groups, despite the high variability in human cell proliferation in the recipients. Thus, HurIL-4 can be used as an adjuvant growth factor which improves successful engraftment of human peripheral blood lymphocytes in scid mice.
authors.affiliation: Experimental Immunology Unit, University of Louvain, Brussels, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: Bombil
authors.forename: D
authors.initials: D
authors.lastname: Latinne
authors.forename: J P
authors.initials: JP
authors.lastname: Kints
authors.forename: H
authors.initials: H
authors.lastname: Bazin
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000032:analysis; D002678:Chimera / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007376:Interleukin-2 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D051379:Mice; D016513:Mice, SCID; D011994:Recombinant Proteins / Q000494:pharmacology*; D013154:Spleen / Q000737:chemistry / Q000276:immunology; D013950:Thymus Gland / Q000737:chemistry / Q000276:immunology
chemical_list: D015415:Biomarkers; D007136:Immunoglobulins; D007376:Interleukin-2; D011994:Recombinant Proteins; D015847:Interleukin-4